fluvoxamino acid: metabolite of fluvoxamine; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 46781165 |
| CHEBI ID | 185823 |
| SCHEMBL ID | 16220938 |
| MeSH ID | M0454031 |
| Synonym |
|---|
| fluvoxamino acid |
| 192876-02-1 |
| desmethyl fluvoxamine |
| CHEBI:185823 |
| (5e)-5-(2-aminoethoxyimino)-5-[4-(triluoromethyl)phenyl]pentan-1-ol |
| unii-y308jh639r |
| y308jh639r , |
| ep impurity g |
| 1-pentanone, 5-hydroxy-1-(4-(trifluoromethyl)phenyl)-, o-(2-aminoethyl)oxime, (1e)- |
| fluvoxamine maleate impurity g [ep impurity] |
| (5e)-5-((2-aminoethoxy)imino)-5-(4-(trifluoromethyl)phenyl)pentan-1-ol |
| DTXSID30172885 |
| SCHEMBL16220938 |
| J-012483 |
| fluvoxamine impurity g |
| (5e)-5-(2-aminoethoxyimino)-5-[4-(trifluoromethyl)phenyl]pentan-1-ol |
| 1-pentanone, 5-hydroxy-1-[4-(trifluoromethyl)phenyl]-, o-(2-aminoethyl)oxime, (1e)- |
| gcsldhtzsdnyec-cpnjwejpsa-n |
| Excerpt | Relevance | Reference |
|---|---|---|
| " This method has been used for the simultaneous determination of steady-state plasma concentration (Css) of fluvoxamine and fluvoxamino acid in depressive patients treated with 200 mg of oral fluvoxamine dosed as 100 mg twice-daily." | ( High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Higuchi, H; Ohkubo, T; Otani, K; Shimizu, T; Shimoyama, R; Yoshida, K, 2003) | 0.76 |
| Class | Description |
|---|---|
| (trifluoromethyl)benzenes | An organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||